The body's natural defenses against B-cell cancers
Central tolerance mechanisms in B-cell malignancies
This research looks at how our body's natural defense system can get rid of harmful B-cells, including those that cause certain types of blood cancer like leukemia and lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11134449 on NIH RePORTER |
What this research studies
Our bodies naturally produce many B-cells each day that could potentially cause harm, but a strong defense system called central tolerance usually removes them to prevent autoimmune diseases. This research has uncovered that this same natural defense also eliminates early forms of B-cell cancers, such as B-cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). By understanding how central tolerance works, we hope to find new ways to target these cancers. This approach could offer a different strategy to overcome drug resistance and reduce side effects for patients living with these conditions.
Who could benefit from this research
Good fit: Patients with B-cell acute lymphoblastic leukemia, mantle cell lymphoma, or chronic lymphocytic leukemia, including both children and adults, could potentially benefit from future treatments developed from this research.
Not a fit: Patients without B-cell malignancies or autoimmune diseases are unlikely to directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new, less toxic treatments for B-cell cancers by harnessing the body's own defense mechanisms.
How similar studies have performed: Previous work by this research team has already shown that central tolerance mechanisms can eliminate B-cell tumors, suggesting a promising foundation for this continued work.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Muschen, Markus — Yale University
- Study coordinator: Muschen, Markus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.